vTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference
July 13 2017 - 4:30PM
Business Wire
vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that
data on the company’s phase 3 Alzheimer’s candidate, azeliragon, an
oral antagonist of the Receptor for Advanced Glycation Endproducts
(RAGE), will be presented at the 2017 Alzheimer's Association
International Conference (AAIC) held in London, England, July 16 –
20, 2017.
Details of the poster presentations are listed below:
Poster Title: “Assessment of Azeliragon QTc Liability
through Integrated, Model-Based Concentration QTc
Analysis”Poster Number: P1-066Category: Therapeutics:
ClinicalDate and Time: Sunday, July 16, 2017, 9:30 am – 4:15
pm GMTLocation: S8
Poster Title: “Effect of Food on the Pharmacokinetics of
Azeliragon in Healthy Adult Subjects”Poster Number:
P2-025Category: Therapeutics: ClinicalDate and Time:
Monday, July 17, 2017, 9:30 am – 4:15 pm GMTLocation: S8
About Azeliragon
Azeliragon, also known as TTP488, is a novel orally active
small-molecule antagonist of RAGE. A broad range of human
pathologic and experimental biologic investigation suggests that
RAGE activation contributes to the pathogenesis of Alzheimer’s
disease. Sustained Amyloid-β interactions with RAGE at the
blood-brain barrier (BBB) and in neuronal and microglial cells,
play potentially major roles in amyloid plaque formation,
neuroinflammation and chronic neural dysfunction – all hallmarks of
Alzheimer’s disease.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and Type 2
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These
forward-looking statements reflect our views with respect to future
events as of the date of this release and are based on assumptions
and subject to risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking
statements. These forward-looking statements represent our
estimates and assumptions only as of the date of this release and,
except as required by law, we undertake no obligation to update or
review publicly any forward-looking statements, whether as a result
of new information, future events or otherwise after the date of
this release. We anticipate that subsequent events and developments
will cause our views to change. Our forward-looking statements do
not reflect the potential impact of any future acquisitions,
merger, dispositions, joint ventures or investments we may
undertake. We qualify all of our forward-looking statements by
these cautionary statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170713006088/en/
Investors:vTv Therapeutics Inc.Michael Gibralter,
646-378-2938IR@vtvtherapeutics.comorMedia:Pure Communications
Inc.Christie Teller, 817-907-3619cteller@w2ogroup.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2023 to Apr 2024